Publicaciones en las que colabora con JUAN JOSÉ TORRADO DURÁN (19)

2023

  1. Design, synthesis and biological evaluation of antiparasitic dinitroaniline-ether phospholipid hybrids

    Bioorganic Chemistry, Vol. 138

  2. Effect of Clindamycin on Intestinal Microbiome and Miltefosine Pharmacology in Hamsters Infected with Leishmania infantum

    Antibiotics, Vol. 12, Núm. 2

2022

  1. Leishmania infantum infection does not affect the main composition of the intestinal microbiome of the Syrian hamster

    Parasites and Vectors, Vol. 15, Núm. 1

2021

  1. Antileishmanial drug discovery and development: Time to reset the model?

    Microorganisms, Vol. 9, Núm. 12

2019

  1. Discovery and Pharmacological Studies of 4-Hydroxyphenyl-Derived Phosphonium Salts Active in a Mouse Model of Visceral Leishmaniasis

    Journal of Medicinal Chemistry, Vol. 62, Núm. 23, pp. 10664-10675

  2. Discovery of a benzothiophene-flavonol halting miltefosine and antimonial drug resistance in Leishmania parasites through the application of medicinal chemistry, screening and genomics

    European Journal of Medicinal Chemistry, Vol. 183

  3. SAR Studies and Biological Characterization of a Chromen-4-one Derivative as an Anti- Trypanosoma brucei Agent

    ACS Medicinal Chemistry Letters, Vol. 10, Núm. 4, pp. 528-533

2018

  1. Pharmacokinetics and disposition of miltefosine in healthy mice and hamsters experimentally infected with Leishmania infantum

    European Journal of Pharmaceutical Sciences, Vol. 121, pp. 281-286

2017

  1. Methoxylated 2'-hydroxychalcones as antiparasitic hit compounds

    European Journal of Medicinal Chemistry, Vol. 126, pp. 1129-1135

2016

  1. Profiling of flavonol derivatives for the development of antitrypanosomatidic drugs

    Journal of Medicinal Chemistry, Vol. 59, Núm. 16, pp. 7598-7616

2013

  1. Hemolytic and pharmacokinetic studies of liposomal and particulate amphotericin B formulations

    International Journal of Pharmaceutics, Vol. 447, Núm. 1-2, pp. 38-46

2010

  1. Rationale and conditions for the requirement of chiral bioanalytical methods in bioequivalence studies

    European Journal of Clinical Pharmacology, Vol. 66, Núm. 6, pp. 599-604

2008

  1. HPLC assay for determination of amphotericin B in biological samples

    Biomedical Chromatography, Vol. 22, Núm. 4, pp. 402-407

2007

  1. In vitro effect of new formulations of amphotericin B on amastigote and promastigote forms of Leishmania infantum

    International Journal of Antimicrobial Agents, Vol. 30, Núm. 4, pp. 325-329

2006

  1. Real-time reverse transcription-PCR quantification of cytokine mRNA expression in golden Syrian hamster infected with Leishmania infantum and treated with a new amphotericin B formulation

    Antimicrobial Agents and Chemotherapy, Vol. 50, Núm. 4, pp. 1195-1201

2005

  1. Influence of the vehicle on the properties and efficacy of microparticles containing amphotericin B

    Journal of Drug Targeting, Vol. 13, Núm. 4, pp. 225-233

2004

  1. Amphotericin B molecular organization as an essential factor to improve activity/toxicity ratio in the treatment of visceral leishmaniasis

    Journal of Drug Targeting, Vol. 12, Núm. 7, pp. 453-460

  2. Anti-leishmanial activity of a new formulation of amphotericin B

    Tropical Medicine and International Health, Vol. 9, Núm. 9, pp. 981-990

  3. Treatment of experimental visceral leishmaniasis with amphotericin B in stable albumin microspheres

    Antimicrobial Agents and Chemotherapy, Vol. 48, Núm. 9, pp. 3246-3252